Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two oral and two poster presentations at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California, December 6-9, 2014. The presentations include preclinical proof-of-concept of Tolero’s Axl kinase inhibitors for the treatment of leukemias and ALK2 inhibitors, which regulate hepcidin, for the treatment of anemia.
Help employers find you! Check out all the jobs and post your resume.
